| # | Title | Journal | Year | Citations |
|---|
| 1 | A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer | Annals of Oncology | 2014 | 297 |
| 2 | FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial | ESMO Open | 2020 | 32 |
| 3 | Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial | European Journal of Cancer | 2021 | 26 |
| 4 | Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis | Journal of Geriatric Oncology | 2018 | 14 |
| 5 | SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013 | Clinical and Translational Oncology | 2013 | 11 |
| 6 | The Medical Oncology resident mentor: situation and workload | Clinical and Translational Oncology | 2019 | 4 |
| 7 | Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study. | Journal of Clinical Oncology | 2019 | 4 |
| 8 | A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC) | Annals of Oncology | 2017 | 3 |
| 9 | Controversies in the treatment of RAS wild-type metastatic colorectal cancer | Clinical and Translational Oncology | 2021 | 3 |
| 10 | Case-Control Analysis of the Impact of Anemia on Quality of Life in Patients with Cancer: A Qca Study Analysis | Cancers | 2021 | 3 |
| 11 | Influence of a multidisciplinary program of diet, exercise, and mindfulness on the quality of life of stage IIa-IIb breast cancer survivors. | Journal of Clinical Oncology | 2021 | 3 |
| 12 | Open, phase II randomized trial of gefitinib alone versus olaparib (AZD2281) plus gefitinib in advanced non-small cell lung cancer (NSCLC) patients (P) with epidermal growth factor receptor (EGFR) mutations: Spanish Lung Cancer Group trial (NCT=1513174/GECP-GOAL). | Journal of Clinical Oncology | 2014 | 3 |
| 13 | Splanchnic vein thrombosis in ambulatory pancreatic cancer patients receiving chemotherapy. | Journal of Clinical Oncology | 2015 | 3 |
| 14 | Drug resistance induced by paclitaxel and carboplatin plasmatic concentrations in lung cancer cell lines. | Journal of Clinical Oncology | 2012 | 2 |
| 15 | Effect of pharmacogenetic-based selection of first-line chemotherapy on response rate and R0 surgery in metastatic CRC patients. | Journal of Clinical Oncology | 2016 | 2 |
| 16 | Treatment sequence in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in a prospective cohort study. | Journal of Clinical Oncology | 2019 | 2 |
| 17 | The prognostic value of detection methylation level panel of gene in DNA circulating after and before treatment in patients with breast cancer. | Journal of Clinical Oncology | 2012 | 2 |
| 18 | Ras Analysis of the Planet Study: Phase Ii Trial of Panitumumab (P) Plus Folfox4 or Folfiri in Subjects with Wild-Type (Wt) Kras Colorectal Cancer (Crc) and Liver-Limited Disease (Lld) | Annals of Oncology | 2014 | 1 |
| 19 | Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ROS study. | Journal of Clinical Oncology | 2021 | 1 |
| 20 | Phase II trial of miniDOX (reduced-dose docetaxel/oxaliplatin/capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC): TTD 08-02. | Journal of Clinical Oncology | 2013 | 1 |
| 21 | GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of PF-299804 (dacomitinib), a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation. | Journal of Clinical Oncology | 2014 | 1 |
| 22 | JEVTCC: Phase II trial of cabazitaxel (Cbz) in patients (pt) with advanced or metastatic transitional-cell carcinoma (mTCC), who progressed before 12 months after cisplatin-based chemotherapy—A Spanish Oncologic Genitourinary Group (SOGUG) study. | Journal of Clinical Oncology | 2015 | 1 |
| 23 | 90 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 8.5 years from the GOTEL trial. | Journal of Clinical Oncology | 2018 | 1 |
| 24 | MDR1 gene expression in peripheral blood as a marker of treatment response in lung cancer. | Journal of Clinical Oncology | 2012 | 1 |
| 25 | Incidence of incidental and symptomatic venous thromboembolism (VTE) and Khorana’s score in ambulatory pancreatic cancer patients receiving chemotherapy. | Journal of Clinical Oncology | 2014 | 1 |
| 26 | A phase IIb trial of docetaxel concurrent with radiotherapy plus hormotherapy versus radio hormonotherapy in high-risk localized prostate cancer (QRT SOGUG trial): Preliminary report for design, tolerance, and toxicity. | Journal of Clinical Oncology | 2015 | 1 |
| 27 | Novel agents’ sequencing following first-line docetaxel in mCRPC patients: CAPRO study. | Journal of Clinical Oncology | 2016 | 1 |
| 28 | Impact of Lymph Node Level Assessment for Survival on Time to Relapse in Biliary Tract Cancers | Annals of Oncology | 2012 | 0 |
| 29 | 606P Role of serum biomarkers of bone metabolism in metastatic castration-resistance prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): PRORADIUM study final results | Annals of Oncology | 2021 | 0 |
| 30 | Epigenetic aspects of triple-negative in patients with breast cancer. | Journal of Clinical Oncology | 2012 | 0 |
| 31 | Implications prognostics of methylation 14-3-3 sigma promoter in peripheral blood cell DNA with nodal involvement status and tumor size for breast cancer patients. | Journal of Clinical Oncology | 2012 | 0 |
| 32 | Significance and clinical outcome of lymph node level assessment in biliary tract cancers. | Journal of Clinical Oncology | 2013 | 0 |
| 33 | Assessment of treatment response with fulvestrant (F) 500 mg in standard clinical practice through a retrospective study: NCT01509625. | Journal of Clinical Oncology | 2013 | 0 |
| 34 | Methylation ESR1 as a potential factor of resistence to HER2/neu therapy in patients with breast cancer. | Journal of Clinical Oncology | 2013 | 0 |
| 35 | A multicenter randomized study comparing temozolomide (TMZ) versus TMZ-plus-bevacizumab (BEV) before standard treatment in unresectable glioblastoma (GBM) patients (p): The GENOM 009 study by the GEINO group. | Journal of Clinical Oncology | 2014 | 0 |
| 36 | Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model (IMRCC), in patients (pt) treated with pazopanib (Pz) as first line for metastatic renal carcinoma (mRC): First results of the SOGUG SPAZO study. | Journal of Clinical Oncology | 2015 | 0 |
| 37 | Safety of cabazitaxel (Cbz) in patients (pt) with metastatic transitional-cell carcinoma (mTCC) progressing to cisplatin-based chemotherapy: Results from the JEVTCC-SOGUG Study. | Journal of Clinical Oncology | 2015 | 0 |
| 38 | Incidence of venous thromboembolism (VTE) and Khorana´s score (KS) in ambulatory high-grade glioma (HGG) patients receiving chemotherapy. | Journal of Clinical Oncology | 2015 | 0 |
| 39 | Single nucleotide polymorphisms (SNPs) as predictors of efficacy of cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). | Journal of Clinical Oncology | 2020 | 0 |
